Literature DB >> 30204854

Influenza Vaccine Effectiveness in the United States During the 2016-2017 Season.

Brendan Flannery1, Jessie R Chung1, Arnold S Monto2, Emily T Martin2, Edward A Belongia3, Huong Q McLean3, Manjusha Gaglani4,5, Kempapura Murthy4, Richard K Zimmerman6, Mary Patricia Nowalk6, Michael L Jackson7, Lisa A Jackson7, Melissa A Rolfes1, Sarah Spencer1, Alicia M Fry1.   

Abstract

BACKGROUND: In recent influenza seasons, the effectiveness of inactivated influenza vaccines against circulating A(H3N2) virus has been lower than against A(H1N1)pdm09 and B viruses, even when circulating viruses remained antigenically similar to vaccine components.
METHODS: During the 2016-2017 influenza season, vaccine effectiveness (VE) across age groups and vaccine types was examined among outpatients with acute respiratory illness at 5 US sites using a test-negative design that compared the odds of vaccination among reverse transcription polymerase chain reaction-confirmed influenza positives and negatives.
RESULTS: Among 7083 enrollees, 1342 (19%) tested positive for influenza A(H3N2), 648 (9%) were positive for influenza B (including B/Yamagata, n = 577), and 5040 (71%) were influenza negative. Vaccine effectiveness was 40% (95% confidence interval [CI], 32% to 46%) against any influenza virus, 33% (95% CI, 23% to 41%) against influenza A(H3N2) viruses, and 53% (95% CI, 43% to 61%) against influenza B viruses.
CONCLUSIONS: The 2016-2017 influenza vaccines provided moderate protection against any influenza among outpatients but were less protective against influenza A(H3N2) viruses than B viruses. Approaches to improving effectiveness against A(H3N2) viruses are needed. Published by Oxford University Press for the Infectious Diseases Society of America 2018.

Entities:  

Keywords:  influenza vaccine; vaccine effectiveness

Mesh:

Substances:

Year:  2019        PMID: 30204854      PMCID: PMC6522684          DOI: 10.1093/cid/ciy775

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   20.999


  25 in total

1.  Efficacy of Recombinant Influenza Vaccine in Adults 50 Years of Age or Older.

Authors:  Lisa M Dunkle; Ruvim Izikson; Peter Patriarca; Karen L Goldenthal; Derek Muse; Janice Callahan; Manon M J Cox
Journal:  N Engl J Med       Date:  2017-06-22       Impact factor: 91.245

Review 2.  Repeated annual influenza vaccination and vaccine effectiveness: review of evidence.

Authors:  Edward A Belongia; Danuta M Skowronski; Huong Q McLean; Catharine Chambers; Maria E Sundaram; Gaston De Serres
Journal:  Expert Rev Vaccines       Date:  2017-06-09       Impact factor: 5.217

3.  Recommended composition of influenza virus vaccines for use in the 2017–2018 northern hemisphere influenza season.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  2017-03-17

4.  Structure and receptor binding preferences of recombinant human A(H3N2) virus hemagglutinins.

Authors:  Hua Yang; Paul J Carney; Jessie C Chang; Zhu Guo; Julie M Villanueva; James Stevens
Journal:  Virology       Date:  2015-01-22       Impact factor: 3.616

5.  The test-negative design for estimating influenza vaccine effectiveness.

Authors:  Michael L Jackson; Jennifer C Nelson
Journal:  Vaccine       Date:  2013-03-13       Impact factor: 3.641

6.  Prevention and Control of Seasonal Influenza with Vaccines.

Authors:  Lisa A Grohskopf; Leslie Z Sokolow; Karen R Broder; Sonja J Olsen; Ruth A Karron; Daniel B Jernigan; Joseph S Bresee
Journal:  MMWR Recomm Rep       Date:  2016-08-26

7.  Influenza vaccine effectiveness in the United States during 2012-2013: variable protection by age and virus type.

Authors:  Huong Q McLean; Mark G Thompson; Maria E Sundaram; Burney A Kieke; Manjusha Gaglani; Kempapura Murthy; Pedro A Piedra; Richard K Zimmerman; Mary Patricia Nowalk; Jonathan M Raviotta; Michael L Jackson; Lisa Jackson; Suzanne E Ohmit; Joshua G Petrie; Arnold S Monto; Jennifer K Meece; Swathi N Thaker; Jessie R Clippard; Sarah M Spencer; Alicia M Fry; Edward A Belongia
Journal:  J Infect Dis       Date:  2014-11-18       Impact factor: 5.226

8.  Interim estimates of 2016/17 vaccine effectiveness against influenza A(H3N2), Canada, January 2017.

Authors:  Danuta M Skowronski; Catharine Chambers; Suzana Sabaiduc; James A Dickinson; Anne-Luise Winter; Gaston De Serres; Steven J Drews; Agatha Jassem; Jonathan B Gubbay; Hugues Charest; Robert Balshaw; Nathalie Bastien; Yan Li; Mel Krajden
Journal:  Euro Surveill       Date:  2017-02-09

9.  Interim adjusted estimates of seasonal influenza vaccine effectiveness - United States, February 2013.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2013-02-22       Impact factor: 17.586

10.  Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains.

Authors:  Seth J Zost; Kaela Parkhouse; Megan E Gumina; Kangchon Kim; Sebastian Diaz Perez; Patrick C Wilson; John J Treanor; Andrea J Sant; Sarah Cobey; Scott E Hensley
Journal:  Proc Natl Acad Sci U S A       Date:  2017-11-06       Impact factor: 11.205

View more
  43 in total

1.  Age-specific effects of vaccine egg adaptation and immune priming on A(H3N2) antibody responses following influenza vaccination.

Authors:  Feng Liu; F Liaini Gross; Stacie N Jefferson; Crystal Holiday; Yaohui Bai; Li Wang; Bin Zhou; Min Z Levine
Journal:  J Clin Invest       Date:  2021-04-15       Impact factor: 14.808

2.  Effectiveness of Partial and Full Influenza Vaccination Among Children Aged <9 Years in Hong Kong, 2011-2019.

Authors:  Huiying Chua; Susan S Chiu; Eunice L Y Chan; Shuo Feng; Mike Y W Kwan; Joshua S C Wong; J S Malik Peiris; Benjamin J Cowling
Journal:  J Infect Dis       Date:  2019-10-08       Impact factor: 5.226

3.  Incorporating Real-time Influenza Detection Into the Test-negative Design for Estimating Influenza Vaccine Effectiveness: The Real-time Test-negative Design (rtTND).

Authors:  Leora R Feldstein; Wesley H Self; Jill M Ferdinands; Adrienne G Randolph; Michael Aboodi; Adrienne H Baughman; Samuel M Brown; Matthew C Exline; D Clark Files; Kevin Gibbs; Adit A Ginde; Michelle N Gong; Carlos G Grijalva; Natasha Halasa; Akram Khan; Christopher J Lindsell; Margaret Newhams; Ithan D Peltan; Matthew E Prekker; Todd W Rice; Nathan I Shapiro; Jay Steingrub; H Keipp Talbot; M Elizabeth Halloran; Manish Patel
Journal:  Clin Infect Dis       Date:  2021-05-04       Impact factor: 9.079

4.  Spread of Antigenically Drifted Influenza A(H3N2) Viruses and Vaccine Effectiveness in the United States During the 2018-2019 Season.

Authors:  Brendan Flannery; Rebecca J Garten Kondor; Jessie R Chung; Manjusha Gaglani; Michael Reis; Richard K Zimmerman; Mary Patricia Nowalk; Michael L Jackson; Lisa A Jackson; Arnold S Monto; Emily T Martin; Edward A Belongia; Huong Q McLean; Sara S Kim; Lenee Blanton; Krista Kniss; Alicia P Budd; Lynnette Brammer; Thomas J Stark; John R Barnes; David E Wentworth; Alicia M Fry; Manish Patel
Journal:  J Infect Dis       Date:  2020-01-01       Impact factor: 5.226

5.  Modeling the Impacts of Clinical Influenza Testing on Influenza Vaccine Effectiveness Estimates.

Authors:  Leora R Feldstein; Jill M Ferdinands; Wesley H Self; Adrienne G Randolph; Michael Aboodi; Adrienne H Baughman; Samuel M Brown; Matthew C Exline; D Clark Files; Kevin Gibbs; Adit A Ginde; Michelle N Gong; Carlos G Grijalva; Natasha Halasa; Akram Khan; Christopher J Lindsell; Margaret Newhams; Ithan D Peltan; Matthew E Prekker; Todd W Rice; Nathan I Shapiro; Jay Steingrub; H Keipp Talbot; M Elizabeth Halloran; Manish Patel
Journal:  J Infect Dis       Date:  2021-12-15       Impact factor: 5.226

6.  An evaluation of a test-negative design for EV-71 vaccine from a randomized controlled trial.

Authors:  Li Zhang; Mingwei Wei; Pengfei Jin; Jingxin Li; Fengcai Zhu
Journal:  Hum Vaccin Immunother       Date:  2021-02-02       Impact factor: 3.452

7.  Sleep touches everything.

Authors:  Brian D Robertson; Jacob C Collen
Journal:  J Clin Sleep Med       Date:  2020-12-15       Impact factor: 4.062

8.  Low Influenza Vaccine Effectiveness Against A(H3N2)-Associated Hospitalizations in 2016-2017 and 2017-2018 of the Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN).

Authors:  Emily T Martin; Caroline Cheng; Joshua G Petrie; Elif Alyanak; Manjusha Gaglani; Donald B Middleton; Shekhar Ghamande; Fernanda P Silveira; Kempapura Murthy; Richard K Zimmerman; Arnold S Monto; Christopher Trabue; H Keipp Talbot; Jill M Ferdinands
Journal:  J Infect Dis       Date:  2021-06-15       Impact factor: 5.226

9.  Differences between Frequentist and Bayesian inference in routine surveillance for influenza vaccine effectiveness: a test-negative case-control study.

Authors:  Michael L Jackson; Jill Ferdinands; Mary Patricia Nowalk; Richard K Zimmerman; Burney Kieke; Manjusha Gaglani; Kempapura Murthy; Joshua G Petrie; Emily T Martin; Jessie R Chung; Brendan Flannery; Lisa A Jackson
Journal:  BMC Public Health       Date:  2021-03-16       Impact factor: 3.295

10.  Evaluation of Influenza Vaccine Effectiveness Among Young Children Receiving Consecutive Versus Nonconsecutive Vaccination During Influenza A(H3N2)-Predominant Seasons.

Authors:  Suchitra Rao; Angela Moss; Molly M Lamb; Edwin J Asturias
Journal:  J Pediatric Infect Dis Soc       Date:  2021-04-03       Impact factor: 3.164

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.